Consecutive Use of T
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
October 03, 2023 13:57 ET | Spherix Global Insights
Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...
With Little Remainin
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
August 31, 2023 16:35 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent...
New Logo.png
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
October 25, 2022 06:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director,...
Pan-Biome Pharmaceuticals, Inc. provides update on its longevity research program: its compounds modulate inflammation, the gut microbiome, and increase lifespan of C. elegans by 30%
December 02, 2021 10:00 ET | Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc., a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Sienna Logo wR.jpg
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
June 10, 2019 09:05 ET | Sienna Biopharmaceuticals, Inc.
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Sienna Logo wR.jpg
Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
May 21, 2019 09:05 ET | Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D.,...
Sienna Logo wR.jpg
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
May 14, 2019 09:05 ET | Sienna Biopharmaceuticals, Inc.
-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120  -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase...
novan logo.jpg
Novan Announces Promising Clinical Results with SB414
August 20, 2018 06:30 ET | Novan, Inc.
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
New Logo.png
November 30, 2017 06:00 ET | Provectus Biopharmaceuticals Inc.
– Responses mediated by multiple pathways, including IL-17, IL-22 and interferons – – Down-regulation of more than 500 disease-related genes; wide range of central “psoriasis-related” genes...
2019 logo_150x35_jpg.jpg
Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
October 18, 2017 07:05 ET | Novan, Inc.
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...